Free Trial

Atyr PHARMA (ATYR) News Today

Atyr PHARMA logo
$3.24 -0.25 (-7.16%)
Closing price 04:00 PM Eastern
Extended Trading
$3.26 +0.01 (+0.46%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Atyr PHARMA INC stock logo
Atyr PHARMA INC (NASDAQ:ATYR) Short Interest Update
Atyr PHARMA INC (NASDAQ:ATYR - Get Free Report) saw a significant growth in short interest in February. As of February 28th, there was short interest totalling 5,260,000 shares, a growth of 20.9% from the February 13th total of 4,350,000 shares. Approximately 6.5% of the shares of the stock are short sold. Based on an average daily volume of 1,140,000 shares, the short-interest ratio is currently 4.6 days.
Atyr PHARMA INC stock logo
Jane A. Gross Purchases 3,750 Shares of Atyr PHARMA INC (NASDAQ:ATYR) Stock
Atyr PHARMA INC (NASDAQ:ATYR - Get Free Report) Director Jane A. Gross acquired 3,750 shares of Atyr PHARMA stock in a transaction that occurred on Monday, March 17th. The stock was bought at an average cost of $4.00 per share, with a total value of $15,000.00. Following the acquisition, the director now directly owns 9,750 shares of the company's stock, valued at approximately $39,000. This trade represents a 62.50 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Atyr PHARMA's (ATYR) "Buy" Rating Reiterated at HC Wainwright
Atyr PHARMA INC stock logo
HC Wainwright Reaffirms Buy Rating for Atyr PHARMA (NASDAQ:ATYR)
HC Wainwright restated a "buy" rating and set a $35.00 price target on shares of Atyr PHARMA in a research report on Friday.
Atyr PHARMA INC stock logo
Atyr PHARMA INC (NASDAQ:ATYR) Receives Average Recommendation of "Buy" from Brokerages
Shares of Atyr PHARMA INC (NASDAQ:ATYR - Get Free Report) have received a consensus rating of "Buy" from the seven analysts that are presently covering the stock, Marketbeat Ratings reports. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating on
Atyr PHARMA INC stock logo
Atyr PHARMA (NASDAQ:ATYR) Issues Earnings Results
Atyr PHARMA (NASDAQ:ATYR - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.05.
Atyr PHARMA INC stock logo
Atyr PHARMA (NASDAQ:ATYR) Announces Quarterly Earnings Results
Atyr PHARMA (NASDAQ:ATYR - Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.23) by $0.05.
aTyr Pharma (ATYR) Gets a Buy from Piper Sandler
aTyr Pharma shares fall as Q4 loss narrows
aTyr Pharma reports Q4 EPS (18c), consensus (23c)
Piper Sandler Remains a Buy on aTyr Pharma (ATYR)
Atyr PHARMA INC stock logo
Atyr PHARMA (ATYR) Projected to Post Earnings on Thursday
Atyr PHARMA (NASDAQ:ATYR) will be releasing earnings before the market opens on Thursday, March 13, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=672341)
Atyr PHARMA INC stock logo
Leerink Partnrs Weighs in on Atyr PHARMA FY2024 Earnings
Atyr PHARMA INC (NASDAQ:ATYR - Free Report) - Analysts at Leerink Partnrs issued their FY2024 earnings estimates for shares of Atyr PHARMA in a research note issued on Tuesday, February 18th. Leerink Partnrs analyst F. Khurshid forecasts that the company will post earnings per share of ($0.89) fo
Atyr PHARMA INC stock logo
Atyr PHARMA INC (NASDAQ:ATYR) Receives $19.25 Average PT from Brokerages
Atyr PHARMA INC (NASDAQ:ATYR - Get Free Report) has received an average rating of "Buy" from the seven brokerages that are presently covering the firm, MarketBeat.com reports. Six investment analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to t
Atyr PHARMA INC stock logo
Atyr PHARMA INC (NASDAQ:ATYR) Receives Consensus Recommendation of "Buy" from Brokerages
Atyr PHARMA INC (NASDAQ:ATYR - Get Free Report) has been assigned a consensus rating of "Buy" from the five research firms that are currently covering the stock, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a buy recommendation. The average 1-year target pr
Atyr PHARMA INC stock logo
Atyr PHARMA (NASDAQ:ATYR) Earns Outperform Rating from Analysts at Leerink Partners
Leerink Partners began coverage on shares of Atyr PHARMA in a research report on Tuesday. They set an "outperform" rating and a $16.00 price target on the stock.
Atyr PHARMA INC stock logo
Atyr PHARMA (NASDAQ:ATYR) Upgraded by Leerink Partnrs to "Strong-Buy" Rating
Leerink Partnrs upgraded Atyr PHARMA to a "strong-buy" rating in a report on Tuesday.
Atyr PHARMA INC stock logo
Atyr PHARMA INC (NASDAQ:ATYR) Short Interest Up 8.5% in January
Atyr PHARMA INC (NASDAQ:ATYR - Get Free Report) was the target of a large growth in short interest in the month of January. As of January 31st, there was short interest totalling 3,820,000 shares, a growth of 8.5% from the January 15th total of 3,520,000 shares. Currently, 4.7% of the shares of the stock are sold short. Based on an average trading volume of 820,000 shares, the short-interest ratio is currently 4.7 days.
RBC Capital Keeps Their Buy Rating on aTyr Pharma (ATYR)
Atyr PHARMA INC stock logo
Atyr PHARMA INC (NASDAQ:ATYR) Short Interest Up 25.0% in January
Atyr PHARMA INC (NASDAQ:ATYR - Get Free Report) saw a large increase in short interest in the month of January. As of January 15th, there was short interest totalling 3,650,000 shares, an increase of 25.0% from the December 31st total of 2,920,000 shares. Approximately 4.5% of the shares of the company are short sold. Based on an average trading volume of 1,060,000 shares, the days-to-cover ratio is presently 3.4 days.
Atyr PHARMA INC stock logo
Brokers Set Expectations for Atyr PHARMA FY2025 Earnings
Atyr PHARMA INC (NASDAQ:ATYR - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Atyr PHARMA in a research note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst P. Agrawal anticipates that the company will earn ($0.
Atyr PHARMA INC stock logo
Short Interest in Atyr PHARMA INC (NASDAQ:ATYR) Expands By 25.0%
Atyr PHARMA INC (NASDAQ:ATYR - Get Free Report) was the target of a large increase in short interest in the month of December. As of December 31st, there was short interest totalling 3,650,000 shares, an increase of 25.0% from the December 15th total of 2,920,000 shares. Currently, 4.5% of the company's shares are sold short. Based on an average daily volume of 1,060,000 shares, the days-to-cover ratio is presently 3.4 days.
Atyr PHARMA INC stock logo
Cantor Fitzgerald Weighs in on Atyr PHARMA FY2024 Earnings
Atyr PHARMA INC (NASDAQ:ATYR - Free Report) - Research analysts at Cantor Fitzgerald issued their FY2024 earnings per share (EPS) estimates for shares of Atyr PHARMA in a report issued on Thursday, January 9th. Cantor Fitzgerald analyst P. Agrawal expects that the company will earn ($0.91) per sh
Atyr PHARMA INC stock logo
Atyr PHARMA (NASDAQ:ATYR) Now Covered by Cantor Fitzgerald
Cantor Fitzgerald initiated coverage on Atyr PHARMA in a research note on Monday. They set an "overweight" rating for the company.
Atyr PHARMA INC stock logo
Atyr PHARMA INC (NASDAQ:ATYR) Sees Significant Increase in Short Interest
Atyr PHARMA INC (NASDAQ:ATYR - Get Free Report) was the target of a significant growth in short interest during the month of December. As of December 15th, there was short interest totalling 2,920,000 shares, a growth of 34.6% from the November 30th total of 2,170,000 shares. Approximately 3.6% of the company's shares are sold short. Based on an average daily trading volume, of 988,700 shares, the short-interest ratio is currently 3.0 days.
aTyr Pharma appoints Eric Benevich to the company’s Board
Remove Ads
Get Atyr PHARMA News Delivered to You Automatically

Sign up to receive the latest news and ratings for ATYR and its competitors with MarketBeat's FREE daily newsletter.

ATYR Media Mentions By Week

ATYR Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ATYR
News Sentiment

0.76

0.89

Average
Medical
News Sentiment

ATYR News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ATYR Articles
This Week

3

2

ATYR Articles
Average Week

Remove Ads
Get Atyr PHARMA News Delivered to You Automatically

Sign up to receive the latest news and ratings for ATYR and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:ATYR) was last updated on 3/26/2025 by MarketBeat.com Staff
From Our Partners